Aytu BioPharma reported quarterly revenue below Wall Street's expectations, and a wider loss than anticipated. The stock fell 14% to $2.16 after the bell on Tuesday.
Cohu plans to offer $200 million in convertible senior notes due in 2031. Shares declined 10% to $20.59 in after-hours trading.
Cyclerion Therapeutics entered a licensing agreement with the Massachusetts Institute of Technology securing intellectual property for its strategic relaunch. The stock soared 39% to $4.21.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 23, 2025 19:17 ET (23:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.